These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 2476996

  • 1. [Factors modifying remission in cytostatic chemotherapy of squamous cell carcinoma recurrence in the area of the head and neck].
    Scherlacher A, Jakse R, Lehnert M, Haas J.
    Laryngorhinootologie; 1989 Aug; 68(8):425-32. PubMed ID: 2476996
    [Abstract] [Full Text] [Related]

  • 2. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
    Recondo G, Armand JP, Tellez-Bernal E, Domenge C, Belehradek M, De Vathaire F, Wibault P, Richard JM, Cvitkovic E.
    Laryngoscope; 1991 May; 101(5):494-501. PubMed ID: 1709437
    [Abstract] [Full Text] [Related]

  • 3. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
    Amrein PC, Fabian RL.
    Laryngoscope; 1992 Aug; 102(8):901-6. PubMed ID: 1379664
    [Abstract] [Full Text] [Related]

  • 4. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
    Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA.
    J Clin Oncol; 2004 Jan 15; 22(2):262-8. PubMed ID: 14722034
    [Abstract] [Full Text] [Related]

  • 5. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A, Koukourakis MI, Sivridis E, Fountzilas G.
    Anticancer Res; 2000 Jan 15; 20(2A):997-1004. PubMed ID: 10810387
    [Abstract] [Full Text] [Related]

  • 6. Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
    Panasci L, Gravenor D, Black M, Frenkiel S, Margolese R.
    Cancer Treat Rep; 1985 Sep 15; 69(9):1015-7. PubMed ID: 2411401
    [Abstract] [Full Text] [Related]

  • 7. [Chemotherapy of recurrent squamous cell carcinomas in the ENT area with cisplatin/adriamycin (DDP/ADM) and methotrexate/5-fluorouracil (MTX/5-Flu): a retrospective comparison of 2 protocols].
    Jakse R, Scherlacher A, Lehnert M, Haas J.
    HNO; 1986 Jun 15; 34(6):235-40. PubMed ID: 3744908
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J.
    Cancer; 1999 Dec 01; 86(11):2364-9. PubMed ID: 10590379
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
    Athanasiadis I, Taylor S, Vokes EE, Pelzer HJ, Rademaker A, Mittal BB, Ganzenko N, Blough R, Lester EP, Kies MS.
    Cancer; 1997 Feb 01; 79(3):588-94. PubMed ID: 9028372
    [Abstract] [Full Text] [Related]

  • 13. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A.
    Jpn J Clin Oncol; 2009 Apr 01; 39(4):225-30. PubMed ID: 19211574
    [Abstract] [Full Text] [Related]

  • 14. Neoadjuvant chemotherapy with cisplatin, methotrexate, bleomycin and vincristine (CABO) in patients with stage III and IV squamous cell carcinoma of the head and neck.
    Recloux P, Dodion PF, Andry G, Chantrain G, Dor P, Buyse M, Van Houtte P, Lemort M, Haesendonck P, Larsimont D.
    Eur J Surg Oncol; 1989 Dec 01; 15(6):568-74. PubMed ID: 2480922
    [Abstract] [Full Text] [Related]

  • 15. [Treatment for recurrent head and neck carcinomas].
    Tsukuda M.
    Gan To Kagaku Ryoho; 1998 Feb 01; 25(3):303-8. PubMed ID: 9492820
    [Abstract] [Full Text] [Related]

  • 16. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 01; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 17. [Chemotherapy or chemotherapy and radiotherapy in advanced head and neck tumors. A prospective, randomized study comparing the 2 therapeutic modalities].
    Klima A, von Ilberg C, Bergmann L, Zoubek A, Klippstein T, Mitrou PS, Szepesi S.
    HNO; 1987 Feb 01; 35(2):78-83. PubMed ID: 2437086
    [Abstract] [Full Text] [Related]

  • 18. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM.
    Cancer J Sci Am; 1997 Feb 01; 3(2):92-9. PubMed ID: 9099459
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Palliative antineoplastic chemotherapy of patients with head and neck tumors].
    Kleemann D, Hingst V, Kramp B.
    HNO; 1994 May 01; 42(5):275-9. PubMed ID: 7519592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.